scholarly journals Administration of adjuvant chemotherapy for stage II-III colon cancer patients: An European population-based study

2017 ◽  
Vol 142 (7) ◽  
pp. 1480-1489 ◽  
Author(s):  
Masoud Babaei ◽  
Yesilda Balavarca ◽  
Lina Jansen ◽  
Valery Lemmens ◽  
Felice N. van Erning ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Population Based ◽  
European Population ◽  
Stage Ii ◽  
Population Based Study

scholarly journals Microsatellite instability and survival after adjuvant chemotherapy among stage II and III colon cancer patients: results from a population‐based study

2020 ◽  
Vol 14 (2) ◽  
pp. 363-372 ◽  
Author(s):  
Elizabeth Alwers ◽  
Lina Jansen ◽  
Hendrik Bläker ◽  
Matthias Kloor ◽  
Katrin E. Tagscherer ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Microsatellite Instability ◽  
Cancer Patients ◽  
Population Based ◽  
Stage Ii ◽  
Population Based Study

Contribution of tumor stroma ratio to a better selection of stage II colon cancer patients into high and low risk groups: A population based study.

2016 ◽  
Vol 34 (15_suppl) ◽  
pp. 3582-3582
Author(s):  
Sanne Kjaer-Frifeldt ◽  
Gabi W. van Pelt ◽  
Rene dePont Christensen ◽  
Wilma E Mesker ◽  
Anders Kristian Moeller Jakobsen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Tumor Stroma ◽  
Risk Groups ◽  
Population Based ◽  
Low Risk ◽  
Stage Ii ◽  
Population Based Study ◽  
Stage Ii Colon Cancer ◽  
Selection Of

The prognostic importance of miRNA-21 in stage II colon cancer: A population-based study.

2012 ◽  
Vol 30 (15_suppl) ◽  
pp. 3513-3513
Author(s):  
Sanne Kjaer-Frifeldt ◽  
Torben Hansen ◽  
Boye Schnack Nielsen ◽  
Stine Joergensen ◽  
Jan Lindebjerg ◽  
...  
Keyword(s):  
Colon Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Population Based ◽  
Stage Ii ◽  
Stromal Compartment ◽  
Cox Regression Analysis ◽  
Prognostic Importance ◽  
Stage Ii Colon Cancer

3513 Background: Adjuvant chemotherapy for stage II colon cancer patients is still controversial and the debate on which patients should be considered as high risk patients is still ongoing. The decision is based on clinical and pathological markers of risk, which are inadequately informative in most of the patients, and better methods are highly needed. The aim of the present study was to investigate the possible prognostic importance of miRNA-21, quantified by in situ hybridization (ISH), in a unique, large population-based cohort of patients treated for stage II colon cancer patients. Methods: The study included all patients diagnosed with stage II colon cancer in Denmark in the year 2003 (711 patients), representing a full population of five million people. Patients receiving adjuvant chemotherapy were excluded (N=15). One paraffin-embedded tissue block was obtained from each patient. A 6μm-thick section was processed for formazan-based chromogenic miR-21 ISH analysis and counter stained with nuclear red. The blue miR-21 ISH signal was assessed by image analysis to obtain two quantitative expression estimates: the total blue area (TB) and the ratio of TB with the nuclear density (TBR). Results: The miRNA-21 signal was predominantly observed in fibroblast-like cells located in the stromal compartment of the tumors. Patients expressing high levels of miRNA-21 (high mean TBR) had significantly inferior cancer specific survival (CSS): HR = 1.26 (95% CI; 1.15-1.60), p <0.001. In the COX regression analysis (including; gender, T-category, malignancy grade, localization, tumor perforation, tumor fixation, number of lymph nodes and MSI status), mean TBR was found to be an independent predictive marker of poor CSS, HR = 1.41 (95%CI; 1.19-1.67, p< 0.001). The same applied to TB. Conclusions: The present study shows that increasing miRNA-21 expression level is significantly correlated to decreasing CSS. Analyses of miRNA-21 should be considered as a potential adjunct in the selection of high risk stage II patients.

Patterns of Referral for Adjuvant Chemotherapy for Stage II and III Colon Cancer: A Population-Based Study

2016 ◽  
Vol 23 (8) ◽  
pp. 2529-2538 ◽  
Author(s):  
Gursimran Chandhoke ◽  
Xuejiao Wei ◽  
Sulaiman Nanji ◽  
James Biagi ◽  
Yingwei Peng ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Population Based ◽  
Stage Ii ◽  
Population Based Study

scholarly journals Impact of timing of adjuvant chemotherapy on survival in stage III colon cancer: a population-based study

BMC Cancer ◽  
2018 ◽  
Vol 18 (1) ◽  
Author(s):  
Peng Gao ◽  
Xuan-zhang Huang ◽  
Yong-xi Song ◽  
Jing-xu Sun ◽  
Xiao-wan Chen ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Adjuvant Chemotherapy ◽  
Population Based ◽  
Stage Iii ◽  
Population Based Study ◽  
Stage Iii Colon Cancer

scholarly journals Population-based study of the effect of gene expression profiling on adjuvant chemotherapy use in breast cancer patients under the age of 65 years

Cancer ◽  
2015 ◽  
Vol 121 (22) ◽  
pp. 4062-4070 ◽  
Author(s):  
Arnold L. Potosky ◽  
Suzanne C. O'Neill ◽  
Claudine Isaacs ◽  
Huei-Ting Tsai ◽  
Calvin Chao ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Gene Expression ◽  
Adjuvant Chemotherapy ◽  
Gene Expression Profiling ◽  
Cancer Patients ◽  
Expression Profiling ◽  
Population Based ◽  
Breast Cancer Patients ◽  
Population Based Study

Variation at presentation among colon cancer patients with metastases: a population-based study

2015 ◽  
Vol 17 (5) ◽  
pp. 403-408 ◽  
Author(s):  
P. A. Heedman ◽  
E. Canslätt ◽  
G. Henriks ◽  
H. Starkhammar ◽  
V. Fomichov ◽  
...  
Keyword(s):  
Colon Cancer ◽  
Cancer Patients ◽  
Population Based ◽  
Population Based Study

Development and validation of a robust prognostic and predictive signature for colorectal cancer (CRC) patients

2009 ◽  
Vol 27 (15_suppl) ◽  
pp. 4036-4036
Author(s):  
A. M. Glas ◽  
P. Roepman ◽  
R. Salazar ◽  
G. Capella ◽  
V. Moreno ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Colon Cancer ◽  
High Risk ◽  
Adjuvant Chemotherapy ◽  
Cancer Patients ◽  
Gene Signature ◽  
Low Risk ◽  
Stage Ii ◽  
Significant Difference ◽  
Independent Cohort

4036 Background: Between 25 and 35% of stage II CRC patients will experience a recurrence of their disease and may benefit from adjuvant chemotherapy. Official guidelines give suggestions but no clear recommendation for best risk stratification. Here we describe the development a robust signature that predicts disease relapse and can assist in treatment decisions. Methods: Fresh frozen tumor tissues from 180 patients with stage I, II and III colorectal cancer undergoing surgery were analyzed using high density Agilent 44K oligonucleotide arrays. Median FU was 70.2 months; 85% of patients did not receive adjuvant chemotherapy. Unsupervised hierarchical clustering based on full-genome gene expression measurement indicated the existence of 3 main colon molecular subclasses. Survival analysis of the 3 classes showed that subtype C (n= 27) had a poor outcome and subtype A (n= 48) good outcome. Only the intermediate group B (n=104) was used to develop a signature by using a cross validation procedure to score all genes for their association with 5-yr distant metastasis free survival (DMFS) and subsequently applied to all samples (n=180). The obtained gene signature was further validated on an independent cohort of 178 stage II + III colon samples. Results: A set of 38 prognosis related gene probes showed robust DMFS association in over 50% of all iterations in the Training Set of 180 samples. The gene signature was validated on an independent cohort of 178 samples from stage II + III colon cancer patients. The profile classified 61% of the validation samples as low-risk and 39% as high-risk. The low- and high-risk samples showed a significant difference in DMFS with a HR of 3.19 (P= 8.5e-4). Five-year DMFS rates were 89% (95%CI 83–95) for low-risk and 62% (95%CI 50–77) for high-risk samples. Moreover, the profile showed a significant performance within stage II (P=0.0058) and III (P=0.036) only samples. The performance of the profile was significant for both untreated (P=0.0082) and treated patients (P=0.016) suggesting that its power is independent of treatment benefits. Conclusions: ColoPrint is able to predict the prognosis of stage II and III colon cancer patients and facilitates the identification of patients who would benefit from adjuvant chemotherapy. [Table: see text]

Sign in / Sign up

Export Citation Format

Share Document